Details for: CD69

Gene ID: 969

Gene Type:  Protein-coding  - A gene that serves as a template for producing a messenger RNA (mRNA) molecule, which is then translated into a functional protein.

Symbol: CD69

Ensembl ID: ENSG00000110848

Description: CD69 molecule

Selected Context(s):  Overall

Cell Significance Landscape

Contexts:

Associated with

Significant Cells

Cell Significance Index (CSI) scores for the chosen context(s)

  • CD4-positive helper T cell CL0000492
    CSI 106.5
    rCSI 80.56%
    PRS 95.47
  • memory B cell CL0000787
    CSI 54.71
    rCSI 54.02%
    PRS 94.04
  • immature B cell CL0000816
    CSI 54.21
    rCSI 40.28%
    PRS 94.09
  • naive B cell CL0000788
    CSI 51.75
    rCSI 44.38%
    PRS 90.79
  • central memory CD4-positive, alpha-beta T cell CL0000904
    CSI 47.21
    rCSI 27.88%
    PRS 97.25
  • CD16-negative, CD56-bright natural killer cell, human CL0000938
    CSI 44.86
    rCSI 33.64%
    PRS 96.6
  • group 3 innate lymphoid cell CL0001071
    CSI 44.26
    rCSI 33.26%
    PRS 90.91
  • T-helper 17 cell CL0000899
    CSI 43.61
    rCSI 34.62%
    PRS 97.41
  • T-helper 1 cell CL0000545
    CSI 42.39
    rCSI 76.52%
    PRS 96.04
  • mucosal invariant T cell CL0000940
    CSI 41.27
    rCSI 33.35%
    PRS 92.87
  • CD8-positive, alpha-beta memory T cell, CD45RO-positive CL0001203
    CSI 40.6
    rCSI 49.19%
    PRS 67.01
  • mature T cell CL0002419
    CSI 40.21
    rCSI 31.27%
    PRS 95.77
  • activated CD4-positive, alpha-beta T cell CL0000896
    CSI 39.47
    rCSI 36.49%
    PRS 96.54
  • CD4-positive, alpha-beta memory T cell CL0000897
    CSI 39.3
    rCSI 28.21%
    PRS 95.94
  • activated type II NK T cell CL0000931
    CSI 38.96
    rCSI 43.85%
    PRS 95.51
  • small pre-B-II cell CL0000954
    CSI 38.27
    rCSI 36.8%
    PRS 95.14
  • naive T cell CL0000898
    CSI 37.76
    rCSI 26.28%
    PRS 96.4
  • naive thymus-derived CD8-positive, alpha-beta T cell CL0000900
    CSI 36.01
    rCSI 25.29%
    PRS 95.09
  • CD8-positive, alpha-beta memory T cell CL0000909
    CSI 35.96
    rCSI 37.56%
    PRS 94.76
  • activated CD8-positive, alpha-beta T cell, human CL0001049
    CSI 33.65
    rCSI 57.56%
    PRS 94.78
  • activated CD8-positive, alpha-beta T cell CL0000906
    CSI 33.53
    rCSI 32.96%
    PRS 95.43
  • microglial cell CL0000129
    CSI 33.41
    rCSI 100%
    PRS 86.05
  • megakaryocyte-erythroid progenitor cell CL0000050
    CSI 33.09
    rCSI 29.88%
    PRS 85.27
  • T follicular helper cell CL0002038
    CSI 32.85
    rCSI 24.59%
    PRS 95.43
  • precursor B cell CL0000817
    CSI 32.77
    rCSI 28.7%
    PRS 91.64
  • mature B cell CL0000785
    CSI 31.82
    rCSI 27.67%
    PRS 93.61
  • gamma-delta T cell CL0000798
    CSI 31.73
    rCSI 37.26%
    PRS 93.59
  • mature NK T cell CL0000814
    CSI 31.64
    rCSI 40.48%
    PRS 91.9
  • B cell CL0000236
    CSI 31.11
    rCSI 41.63%
    PRS 89.6
  • CD4-positive, alpha-beta T cell CL0000624
    CSI 30.7
    rCSI 39.29%
    PRS 91.88
  • effector memory CD4-positive, alpha-beta T cell CL0000905
    CSI 29.77
    rCSI 40.56%
    PRS 97.17
  • naive thymus-derived CD4-positive, alpha-beta T cell CL0000895
    CSI 29.37
    rCSI 36.91%
    PRS 95.7
  • CD16-positive, CD56-dim natural killer cell, human CL0000939
    CSI 28.5
    rCSI 18.99%
    PRS 93.84
  • memory T cell CL0000813
    CSI 28.46
    rCSI 54.82%
    PRS 97.07
  • pro-B cell CL0000826
    CSI 28.22
    rCSI 23.37%
    PRS 88.56
  • effector CD8-positive, alpha-beta T cell CL0001050
    CSI 27.85
    rCSI 21.19%
    PRS 95.93
  • dendritic cell CL0000451
    CSI 27.4
    rCSI 33.76%
    PRS 87.4
  • IgA plasma cell CL0000987
    CSI 26.88
    rCSI 27.52%
    PRS 90.47
  • basophil CL0000767
    CSI 26.78
    rCSI 56.66%
    PRS 93.63
  • monocyte CL0000576
    CSI 26.66
    rCSI 48.19%
    PRS 88.92
  • alpha-beta T cell CL0000789
    CSI 25.65
    rCSI 30.06%
    PRS 95.72
  • unswitched memory B cell CL0000970
    CSI 25.32
    rCSI 21.3%
    PRS 95.7
  • hematopoietic stem cell CL0000037
    CSI 25.24
    rCSI 16.78%
    PRS 88.53
  • T cell CL0000084
    CSI 25.03
    rCSI 48.93%
    PRS 95.14
  • CD8-positive, alpha-beta cytotoxic T cell CL0000794
    CSI 24.75
    rCSI 29.55%
    PRS 96.51
  • double-positive, alpha-beta thymocyte CL0000809
    CSI 21.12
    rCSI 21.52%
    PRS 93.33
  • natural T-regulatory cell CL0000903
    CSI 19.85
    rCSI 37.6%
    PRS 97.76
  • mononuclear phagocyte CL0000113
    CSI 19.75
    rCSI 43.47%
    PRS 89.47
  • mast cell CL0000097
    CSI 18.85
    rCSI 40.71%
    PRS 87.12
  • class switched memory B cell CL0000972
    CSI 18.63
    rCSI 13.91%
    PRS 94.87
  • double negative thymocyte CL0002489
    CSI 18.34
    rCSI 12.75%
    PRS 95.32
  • innate lymphoid cell CL0001065
    CSI 18.11
    rCSI 37.38%
    PRS 81.89
  • follicular B cell CL0000843
    CSI 17.6
    rCSI 63.99%
    PRS 95.22
  • central memory CD8-positive, alpha-beta T cell CL0000907
    CSI 16.26
    rCSI 10.95%
    PRS 95.94
  • early lymphoid progenitor CL0000936
    CSI 16.1
    rCSI 14.14%
    PRS 90.36
  • effector memory CD8-positive, alpha-beta T cell CL0000913
    CSI 15.86
    rCSI 14.44%
    PRS 95.23
  • transitional stage B cell CL0000818
    CSI 15.85
    rCSI 51.89%
    PRS 96.04
  • granulocyte CL0000094
    CSI 15.25
    rCSI 23.3%
    PRS 91.95
  • common lymphoid progenitor CL0000051
    CSI 14.98
    rCSI 20.02%
    PRS 96.39
  • plasmacytoid dendritic cell, human CL0001058
    CSI 14.35
    rCSI 10.02%
    PRS 90.01
  • group 2 innate lymphoid cell CL0001069
    CSI 13.59
    rCSI 73.51%
    PRS 96.89
  • CD4-positive, alpha-beta cytotoxic T cell CL0000934
    CSI 11.86
    rCSI 16.3%
    PRS 96.58
  • intraepithelial lymphocyte CL0002496
    CSI 11.53
    rCSI 31.39%
    PRS 96.43
  • common dendritic progenitor CL0001029
    CSI 11.42
    rCSI 14.34%
    PRS 92.74
  • activated CD4-positive, alpha-beta T cell, human CL0001043
    CSI 11.39
    rCSI 27.4%
    PRS 97.12
  • regulatory T cell CL0000815
    CSI 10.72
    rCSI 12.42%
    PRS 83.45
  • Langerhans cell CL0000453
    CSI 10.69
    rCSI 16.33%
    PRS 94.25
  • lung macrophage CL1001603
    CSI 10.26
    rCSI 22.92%
    PRS 91.96
  • platelet CL0000233
    CSI 9.85
    rCSI 40.87%
    PRS 83.54
  • erythrocyte CL0000232
    CSI 9.74
    rCSI 22.1%
    PRS 85.9
  • CD14-positive, CD16-positive monocyte CL0002397
    CSI 9.37
    rCSI 12.27%
    PRS 94.14
  • lung resident memory CD8-positive, alpha-beta T cell CL4033039
    CSI 9.27
    rCSI 24%
    PRS 96.74
  • large pre-B-II cell CL0000957
    CSI 9.06
    rCSI 25.86%
    PRS 88.82
  • granulocyte monocyte progenitor cell CL0000557
    CSI 8.91
    rCSI 7.72%
    PRS 89.54
  • elicited macrophage CL0000861
    CSI 8.85
    rCSI 8.12%
    PRS 92.25
  • intermediate monocyte CL0002393
    CSI 8.69
    rCSI 13.1%
    PRS 91.07
  • CD1c-positive myeloid dendritic cell CL0002399
    CSI 8.66
    rCSI 10.46%
    PRS 92.36
  • plasmablast CL0000980
    CSI 8.31
    rCSI 6.54%
    PRS 89.99
  • helper T cell CL0000912
    CSI 8
    rCSI 11.31%
    PRS 83.61
  • CD4-positive, CD25-positive, alpha-beta regulatory T cell CL0000792
    CSI 7.96
    rCSI 7.81%
    PRS 95.92
  • alveolar macrophage CL0000583
    CSI 7.71
    rCSI 12.69%
    PRS 89.22
  • CD4-positive, alpha-beta thymocyte CL0000810
    CSI 7.42
    rCSI 5.94%
    PRS 94.41
  • mature alpha-beta T cell CL0000791
    CSI 7.34
    rCSI 26.58%
    PRS 97.27
  • IgG plasma cell CL0000985
    CSI 7.27
    rCSI 8.7%
    PRS 92.82
  • late pro-B cell CL0002048
    CSI 7.23
    rCSI 18.11%
    PRS 95.14
  • CD8-positive, CD28-negative, alpha-beta regulatory T cell CL0000920
    CSI 6.56
    rCSI 13.08%
    PRS 94.65
  • effector memory CD8-positive, alpha-beta T cell, terminally differentiated CL0001062
    CSI 6.52
    rCSI 32.71%
    PRS 95.15
  • effector CD4-positive, alpha-beta T cell CL0001044
    CSI 6.36
    rCSI 18.25%
    PRS 97.56
  • germinal center B cell CL0000844
    CSI 6.31
    rCSI 18.83%
    PRS 92.43
  • dendritic cell, human CL0001056
    CSI 6.3
    rCSI 9.67%
    PRS 92.98
  • megakaryocyte CL0000556
    CSI 5.68
    rCSI 24.63%
    PRS 89.45
  • common myeloid progenitor CL0000049
    CSI 5.58
    rCSI 4.51%
    PRS 88.4
  • CD34-positive, CD56-positive, CD117-positive common innate lymphoid precursor, human CL0001074
    CSI 5.05
    rCSI 58.66%
    PRS 95.84
  • endothelial cell of placenta CL0009092
    CSI 5.01
    rCSI 24.7%
    PRS 91.83
  • fraction A pre-pro B cell CL0002045
    CSI 4.9
    rCSI 5.61%
    PRS 92.78
  • lymphoid lineage restricted progenitor cell CL0000838
    CSI 4.48
    rCSI 17.42%
    PRS 96.62
  • IgM plasma cell CL0000986
    CSI 4.28
    rCSI 19.28%
    PRS 95.59
  • CD8-alpha-alpha-positive, alpha-beta intraepithelial T cell CL0000915
    CSI 4.16
    rCSI 18.89%
    PRS 96.2
  • CD8-positive, alpha-beta thymocyte CL0000811
    CSI 3.9
    rCSI 6.08%
    PRS 95.92
  • cord blood hematopoietic stem cell CL2000095
    CSI 3.55
    rCSI 68.09%
    PRS 94.84
  • double negative T regulatory cell CL0011024
    CSI 0.3
    rCSI 5.0%
    PRS 95.6%
  • pro-T cell CL0000827
    CSI 0.3
    rCSI 7.6%
    PRS 98.1%
  • CD14-positive, CD16-negative classical monocyte CL0002057
    CSI 0.5
    rCSI 3.1%
    PRS 93.7%
  • type EC enteroendocrine cell CL0000577
    CSI 0.8
    rCSI 3.0%
    PRS 88.7%
  • erythroid progenitor cell CL0000038
    CSI 1.1
    rCSI 6.2%
    PRS 89.8%
  • group 3 innate lymphoid cell, human CL0001078
    CSI 1.3
    rCSI 26.7%
    PRS 94.2%
  • tissue-resident macrophage CL0000864
    CSI 1.4
    rCSI 6.4%
    PRS 94.4%
  • B-1 B cell CL0000819
    CSI 1.4
    rCSI 36.5%
    PRS 95.8%
  • decidual natural killer cell, human CL0002343
    CSI 1.6
    rCSI 16.5%
    PRS 93.3%
  • myofibroblast cell CL0000186
    CSI 1.7
    rCSI 2.3%
    PRS 83.2%
  • hepatic pit cell CL2000054
    CSI 1.9
    rCSI 25.3%
    PRS 93.7%
  • myeloid lineage restricted progenitor cell CL0000839
    CSI 1.9
    rCSI 9.8%
    PRS 96.1%
  • B-2 B cell CL0000822
    CSI 1.9
    rCSI 41.2%
    PRS 95.5%
  • eosinophil CL0000771
    CSI 2.0
    rCSI 13.1%
    PRS 96.2%
  • myeloid dendritic cell CL0000782
    CSI 2.0
    rCSI 2.9%
    PRS 95.4%
  • megakaryocyte progenitor cell CL0000553
    CSI 2.1
    rCSI 38.8%
    PRS 97.0%
  • thymocyte CL0000893
    CSI 2.3
    rCSI 8.1%
    PRS 97.7%
  • NKp44-negative group 3 innate lymphoid cell, human CL0001080
    CSI 2.4
    rCSI 75.7%
    PRS 96.5%
  • cytotoxic T cell CL0000910
    CSI 2.5
    rCSI 14.0%
    PRS 87.5%
  • promyelocyte CL0000836
    CSI 2.7
    rCSI 3.9%
    PRS 90.2%
  • myeloid dendritic cell, human CL0001057
    CSI 2.7
    rCSI 15.4%
    PRS 95.3%
  • NKp44-positive group 3 innate lymphoid cell, human CL0001079
    CSI 3.1
    rCSI 44.0%
    PRS 98.6%
  • myeloid leukocyte CL0000766
    CSI 3.2
    rCSI 2.9%
    PRS 87.7%
  • cord blood hematopoietic stem cell CL2000095
    CSI 3.6
    rCSI 68.1%
    PRS 94.8%
  • CD8-positive, alpha-beta thymocyte CL0000811
    CSI 3.9
    rCSI 6.1%
    PRS 95.9%
  • CD8-alpha-alpha-positive, alpha-beta intraepithelial T cell CL0000915
    CSI 4.2
    rCSI 18.9%
    PRS 96.2%
  • IgM plasma cell CL0000986
    CSI 4.3
    rCSI 19.3%
    PRS 95.6%
  • lymphoid lineage restricted progenitor cell CL0000838
    CSI 4.5
    rCSI 17.4%
    PRS 96.6%
  • fraction A pre-pro B cell CL0002045
    CSI 4.9
    rCSI 5.6%
    PRS 92.8%
  • endothelial cell of placenta CL0009092
    CSI 5.0
    rCSI 24.7%
    PRS 91.8%
  • CD34-positive, CD56-positive, CD117-positive common innate lymphoid precursor, human CL0001074
    CSI 5.1
    rCSI 58.7%
    PRS 95.8%
  • common myeloid progenitor CL0000049
    CSI 5.6
    rCSI 4.5%
    PRS 88.4%
  • megakaryocyte CL0000556
    CSI 5.7
    rCSI 24.6%
    PRS 89.5%
  • dendritic cell, human CL0001056
    CSI 6.3
    rCSI 9.7%
    PRS 93.0%
  • germinal center B cell CL0000844
    CSI 6.3
    rCSI 18.8%
    PRS 92.4%
  • effector CD4-positive, alpha-beta T cell CL0001044
    CSI 6.4
    rCSI 18.3%
    PRS 97.6%
  • effector memory CD8-positive, alpha-beta T cell, terminally differentiated CL0001062
    CSI 6.5
    rCSI 32.7%
    PRS 95.2%
  • CD8-positive, CD28-negative, alpha-beta regulatory T cell CL0000920
    CSI 6.6
    rCSI 13.1%
    PRS 94.7%
  • late pro-B cell CL0002048
    CSI 7.2
    rCSI 18.1%
    PRS 95.1%
  • IgG plasma cell CL0000985
    CSI 7.3
    rCSI 8.7%
    PRS 92.8%
  • mature alpha-beta T cell CL0000791
    CSI 7.3
    rCSI 26.6%
    PRS 97.3%
  • CD4-positive, alpha-beta thymocyte CL0000810
    CSI 7.4
    rCSI 5.9%
    PRS 94.4%
  • alveolar macrophage CL0000583
    CSI 7.7
    rCSI 12.7%
    PRS 89.2%
  • CD4-positive, CD25-positive, alpha-beta regulatory T cell CL0000792
    CSI 8.0
    rCSI 7.8%
    PRS 95.9%
  • helper T cell CL0000912
    CSI 8.0
    rCSI 11.3%
    PRS 83.6%
  • plasmablast CL0000980
    CSI 8.3
    rCSI 6.5%
    PRS 90.0%
  • CD1c-positive myeloid dendritic cell CL0002399
    CSI 8.7
    rCSI 10.5%
    PRS 92.4%
  • intermediate monocyte CL0002393
    CSI 8.7
    rCSI 13.1%
    PRS 91.1%
  • elicited macrophage CL0000861
    CSI 8.9
    rCSI 8.1%
    PRS 92.3%
  • granulocyte monocyte progenitor cell CL0000557
    CSI 8.9
    rCSI 7.7%
    PRS 89.5%
  • large pre-B-II cell CL0000957
    CSI 9.1
    rCSI 25.9%
    PRS 88.8%
  • lung resident memory CD8-positive, alpha-beta T cell CL4033039
    CSI 9.3
    rCSI 24.0%
    PRS 96.7%
  • CD14-positive, CD16-positive monocyte CL0002397
    CSI 9.4
    rCSI 12.3%
    PRS 94.1%
  • erythrocyte CL0000232
    CSI 9.7
    rCSI 22.1%
    PRS 85.9%
  • platelet CL0000233
    CSI 9.9
    rCSI 40.9%
    PRS 83.5%
  • lung macrophage CL1001603
    CSI 10.3
    rCSI 22.9%
    PRS 92.0%
  • Langerhans cell CL0000453
    CSI 10.7
    rCSI 16.3%
    PRS 94.3%
  • regulatory T cell CL0000815
    CSI 10.7
    rCSI 12.4%
    PRS 83.5%
  • activated CD4-positive, alpha-beta T cell, human CL0001043
    CSI 11.4
    rCSI 27.4%
    PRS 97.1%
  • common dendritic progenitor CL0001029
    CSI 11.4
    rCSI 14.3%
    PRS 92.7%
  • intraepithelial lymphocyte CL0002496
    CSI 11.5
    rCSI 31.4%
    PRS 96.4%
  • CD4-positive, alpha-beta cytotoxic T cell CL0000934
    CSI 11.9
    rCSI 16.3%
    PRS 96.6%
  • group 2 innate lymphoid cell CL0001069
    CSI 13.6
    rCSI 73.5%
    PRS 96.9%
  • plasmacytoid dendritic cell, human CL0001058
    CSI 14.4
    rCSI 10.0%
    PRS 90.0%
  • common lymphoid progenitor CL0000051
    CSI 15.0
    rCSI 20.0%
    PRS 96.4%
  • granulocyte CL0000094
    CSI 15.3
    rCSI 23.3%
    PRS 92.0%
  • transitional stage B cell CL0000818
    CSI 15.9
    rCSI 51.9%
    PRS 96.0%
  • effector memory CD8-positive, alpha-beta T cell CL0000913
    CSI 15.9
    rCSI 14.4%
    PRS 95.2%
  • early lymphoid progenitor CL0000936
    CSI 16.1
    rCSI 14.1%
    PRS 90.4%
  • central memory CD8-positive, alpha-beta T cell CL0000907
    CSI 16.3
    rCSI 11.0%
    PRS 95.9%
  • follicular B cell CL0000843
    CSI 17.6
    rCSI 64.0%
    PRS 95.2%
  • innate lymphoid cell CL0001065
    CSI 18.1
    rCSI 37.4%
    PRS 81.9%
  • double negative thymocyte CL0002489
    CSI 18.3
    rCSI 12.8%
    PRS 95.3%
  • class switched memory B cell CL0000972
    CSI 18.6
    rCSI 13.9%
    PRS 94.9%
  • mast cell CL0000097
    CSI 18.9
    rCSI 40.7%
    PRS 87.1%
  • mononuclear phagocyte CL0000113
    CSI 19.8
    rCSI 43.5%
    PRS 89.5%
  • natural T-regulatory cell CL0000903
    CSI 19.9
    rCSI 37.6%
    PRS 97.8%
  • double-positive, alpha-beta thymocyte CL0000809
    CSI 21.1
    rCSI 21.5%
    PRS 93.3%
  • CD8-positive, alpha-beta cytotoxic T cell CL0000794
    CSI 24.8
    rCSI 29.6%
    PRS 96.5%
  • T cell CL0000084
    CSI 25.0
    rCSI 48.9%
    PRS 95.1%
  • hematopoietic stem cell CL0000037
    CSI 25.2
    rCSI 16.8%
    PRS 88.5%
  • unswitched memory B cell CL0000970
    CSI 25.3
    rCSI 21.3%
    PRS 95.7%
  • alpha-beta T cell CL0000789
    CSI 25.7
    rCSI 30.1%
    PRS 95.7%
  • monocyte CL0000576
    CSI 26.7
    rCSI 48.2%
    PRS 88.9%
  • basophil CL0000767
    CSI 26.8
    rCSI 56.7%
    PRS 93.6%
  • IgA plasma cell CL0000987
    CSI 26.9
    rCSI 27.5%
    PRS 90.5%
  • dendritic cell CL0000451
    CSI 27.4
    rCSI 33.8%
    PRS 87.4%
  • effector CD8-positive, alpha-beta T cell CL0001050
    CSI 27.9
    rCSI 21.2%
    PRS 95.9%
  • pro-B cell CL0000826
    CSI 28.2
    rCSI 23.4%
    PRS 88.6%
  • memory T cell CL0000813
    CSI 28.5
    rCSI 54.8%
    PRS 97.1%
  • CD16-positive, CD56-dim natural killer cell, human CL0000939
    CSI 28.5
    rCSI 19.0%
    PRS 93.8%
  • naive thymus-derived CD4-positive, alpha-beta T cell CL0000895
    CSI 29.4
    rCSI 36.9%
    PRS 95.7%
  • effector memory CD4-positive, alpha-beta T cell CL0000905
    CSI 29.8
    rCSI 40.6%
    PRS 97.2%
  • CD4-positive, alpha-beta T cell CL0000624
    CSI 30.7
    rCSI 39.3%
    PRS 91.9%
  • B cell CL0000236
    CSI 31.1
    rCSI 41.6%
    PRS 89.6%
  • mature NK T cell CL0000814
    CSI 31.6
    rCSI 40.5%
    PRS 91.9%
  • gamma-delta T cell CL0000798
    CSI 31.7
    rCSI 37.3%
    PRS 93.6%
  • mature B cell CL0000785
    CSI 31.8
    rCSI 27.7%
    PRS 93.6%
  • precursor B cell CL0000817
    CSI 32.8
    rCSI 28.7%
    PRS 91.6%
  • T follicular helper cell CL0002038
    CSI 32.9
    rCSI 24.6%
    PRS 95.4%

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration

Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.

Comma-separated if multiple.
Comma-separated if multiple.

Legend:
  • Query Gene
  • Node Color (Target Cell CSI, relative to current network):
    • Very High
    • High
    • Medium
    • Low
    • Very Low
    • CSI N/A
  • Node Size: Proportional to Target Cell CSI magnitude
  • STRING PPI Edge
  • Shared Pathway Edge (ONTOLOGY)

Loading network (please wait)...

Other Information

This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.

## Summary [CD69](/details-gene/969) is a protein-coding gene located on chromosome 12p13.31 that encodes a C-type lectin domain-containing protein. It is well-established as a type II integral membrane protein and one of the earliest markers of lymphocyte activation ([Link](https://pubmed.ncbi.nlm.nih.gov/8496594/)). Functionally, [CD69](/details-gene/969) acts as a transmembrane signaling receptor involved in regulating lymphocyte proliferation, differentiation, and tissue retention. Expression data highlights its profound significance across a wide range of lymphoid cells, with the highest importance observed in [CD4-positive helper T cells](/details-cell/CL0000492), followed by various B cell and innate lymphoid cell subsets. Its association with clinical phenotypes is noted in OMIM ([107273](https://omim.org/entry/107273)). ## Cellular Roles and Expression Landscape The expression profile of [CD69](/details-gene/969) underscores its central role as a marker of cellular activation, primarily within the hematopoietic system. **Overall**, the gene exhibits its highest significance in lymphocyte populations, suggesting a conserved function across both adaptive and innate immunity. Its most prominent role is in T lymphocytes, with a top CSI score in [CD4-positive helper T cells](/details-cell/CL0000492) (CSI: 106.50). This high significance extends to various T cell subsets, including [central memory CD4-positive, alpha-beta T cells](/details-cell/CL0000904), [T-helper 17 cells](/details-cell/CL0000899), and [activated CD4-positive, alpha-beta T cells](/details-cell/CL0000896), confirming its identity as a pan-activation marker for T cells. Beyond T cells, [CD69](/details-gene/969) is also a key marker for B lymphocytes, showing high CSI scores in [memory B cells](/details-cell/CL0000787), [immature B cells](/details-cell/CL0000816), and [naive B cells](/details-cell/CL0000788). This indicates its involvement throughout B cell development and activation. Furthermore, its significance in innate lymphoid cells, such as [CD16-negative, CD56-bright natural killer cells, human](/details-cell/CL0000938) and [group 3 innate lymphoid cells](/details-cell/CL0001071), points to a broader role in the initial stages of the immune response. The collective expression pattern establishes [CD69](/details-gene/969) as a cornerstone molecule in lymphocyte biology. ## Pathways and Molecular Function [CD69](/details-gene/969) functions primarily as a transmembrane signaling receptor located on the `External side of plasma membrane` ([GO:0009897](https://www.ebi.ac.uk/QuickGO/term/GO:0009897)). Its molecular function includes `Carbohydrate binding` ([GO:0030246](https://www.ebi.ac.uk/QuickGO/term/GO:0030246)), characteristic of its C-type lectin structure, which facilitates interactions with various ligands ([Link](https://doi.org/10.1021/bi0018180)). The biological processes mediated by [CD69](/details-gene/969) are central to immune regulation. It is involved in the `Negative regulation of t cell migration` ([GO:2000405](https://www.ebi.ac.uk/QuickGO/term/GO:2000405)), a critical function for retaining activated lymphocytes at sites of inflammation. This is achieved, in part, through its newly discovered role as an agonist for the sphingosine-1-phosphate receptor 1 (S1PR1), which it sequesters and functionally antagonizes, thereby preventing T cell egress from tissues ([Link](https://doi.org/10.7554/elife.88204)). Furthermore, [CD69](/details-gene/969) plays a role in T cell differentiation, including the `Negative regulation of t-helper 17 cell lineage commitment` ([GO:2000329](https://www.ebi.ac.uk/QuickGO/term/GO:2000329)). This is consistent with studies showing that its interaction with ligands like galectin-1 and the S100A8/S100A9 complex can influence T cell fate decisions, such as the balance between regulatory and effector T cells ([Link](https://doi.org/10.1128/mcb.00348-14), [Link](https://doi.org/10.1096/fj.15-273987)). ## Research Directions The well-defined role of [CD69](/details-gene/969) as an early activation marker on lymphocytes, coupled with its function in cell retention and differentiation, presents several avenues for future research and therapeutic development. **Proposed Hypotheses:** 1. Given its high significance in multiple B cell subsets ([memory B cell](/details-cell/CL0000787), [immature B cell](/details-cell/CL0000816)), it is hypothesized that [CD69](/details-gene/969) engagement on B cells is a key checkpoint for their tissue-specific retention and subsequent differentiation into plasma cells within secondary lymphoid organs. 2. Based on its high expression on [T-helper 17 cells](/details-cell/CL0000899) and its documented role in regulating their lineage commitment ([GO:2000329](https://www.ebi.ac.uk/QuickGO/term/GO:2000329)), we hypothesize that targeting [CD69](/details-gene/969) with a specific antagonist can disrupt Th17 cell function and retention in tissues, representing a therapeutic strategy for Th17-mediated autoimmune diseases like psoriasis or multiple sclerosis. **Experimental Approach:** To test the second hypothesis, primary human naive CD4+ T cells could be cultured under Th17-polarizing conditions in the presence of a [CD69](/details-gene/969) blocking antibody or a small molecule inhibitor. The impact on Th17 differentiation would be quantified by measuring the frequency of IL-17A- and RORγt-positive cells via flow cytometry. A parallel assessment using RNA-seq would reveal the downstream transcriptional programs regulated by [CD69](/details-gene/969) signaling during Th17 commitment. Additionally, a trans-well migration assay could be used to determine if blocking [CD69](/details-gene/969) restores cell migration in response to an S1P gradient, functionally validating its role in T cell retention. **Therapeutic Potential:** As a cell surface protein expressed transiently on activated lymphocytes, [CD69](/details-gene/969) is an excellent candidate for therapeutic intervention. Its role in cell retention makes it a compelling target for **inhibition** in the context of autoimmune and inflammatory diseases, where preventing the accumulation of pathogenic lymphocytes in tissues like the gut, skin, or central nervous system is a primary goal. An antibody-based therapy targeting [CD69](/details-gene/969) could serve to block its S1PR1-modulating function, thereby promoting the egress of inflammatory cells from tissues. This strategy could offer a more targeted approach than systemic S1P receptor modulators, potentially reducing off-target effects.

Genular Protein ID: 3292455730

Symbol: CD69_HUMAN

Name: Early activation antigen CD69

UniProtKB Accession Codes:

Database IDs:

Citations:

PubMed ID: 8496594

Title: Expression cloning of the early activation antigen CD69, a type II integral membrane protein with a C-type lectin domain.

PubMed ID: 8496594

PubMed ID: 8340758

Title: Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors.

PubMed ID: 8340758

DOI: 10.1084/jem.178.2.537

PubMed ID: 8100776

Title: Molecular characterization of the early activation antigen CD69: a type II membrane glycoprotein related to a family of natural killer cell activation antigens.

PubMed ID: 8100776

DOI: 10.1002/eji.1830230737

PubMed ID: 8026529

Title: Structure of the gene coding for the human early lymphocyte activation antigen CD69: a C-type lectin receptor evolutionarily related with the gene families of natural killer cell-specific receptors.

PubMed ID: 8026529

DOI: 10.1002/eji.1830240735

PubMed ID: 15489334

Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).

PubMed ID: 15489334

DOI: 10.1101/gr.2596504

PubMed ID: 23186163

Title: Toward a comprehensive characterization of a human cancer cell phosphoproteome.

PubMed ID: 23186163

DOI: 10.1021/pr300630k

PubMed ID: 24752896

Title: The leukocyte activation receptor CD69 controls T cell differentiation through its interaction with galectin-1.

PubMed ID: 24752896

DOI: 10.1128/mcb.00348-14

PubMed ID: 26296369

Title: Glycosylation-dependent interaction between CD69 and S100A8/S100A9 complex is required for regulatory T-cell differentiation.

PubMed ID: 26296369

DOI: 10.1096/fj.15-273987

PubMed ID: 34841721

Title: CD69 mediates the protective role of adipose tissue-derived mesenchymal stem cells against Pseudomonas aeruginosa pulmonary infection.

PubMed ID: 34841721

DOI: 10.1002/ctm2.563

PubMed ID: 35930205

Title: CD69-oxLDL ligand engagement induces Programmed Cell Death 1 (PD-1) expression in human CD4 + T lymphocytes.

PubMed ID: 35930205

DOI: 10.1007/s00018-022-04481-1

PubMed ID: 11101293

Title: Crystal structure of human CD69: a C-type lectin-like activation marker of hematopoietic cells.

PubMed ID: 11101293

DOI: 10.1021/bi0018180

PubMed ID: 11036086

Title: Crystal structure of the C-type lectin-like domain from the human hematopoietic cell receptor CD69.

PubMed ID: 11036086

DOI: 10.1074/jbc.m008573200

PubMed ID: 18959746

Title: Soluble recombinant CD69 receptors optimized to have an exceptional physical and chemical stability display prolonged circulation and remain intact in the blood of mice.

PubMed ID: 18959746

DOI: 10.1111/j.1742-4658.2008.06683.x

PubMed ID: 37039481

Title: Transmembrane protein CD69 acts as an S1PR1 agonist.

PubMed ID: 37039481

DOI: 10.7554/elife.88204

Sequence Information:

  • Length: 199
  • Mass: 22559
  • Checksum: 172E2699D2FB8DFB
  • Sequence:
  • MSSENCFVAE NSSLHPESGQ ENDATSPHFS TRHEGSFQVP VLCAVMNVVF ITILIIALIA 
    LSVGQYNCPG QYTFSMPSDS HVSSCSEDWV GYQRKCYFIS TVKRSWTSAQ NACSEHGATL 
    AVIDSEKDMN FLKRYAGREE HWVGLKKEPG HPWKWSNGKE FNNWFNVTGS DKCVFLKNTE 
    VSSMECEKNL YWICNKPYK